News

Shielding US Big Pharma from Indian Competitors: USFDA Scrutiny or Protectionism?

Is USFDA's regulatory tool being wielded selectively to stifle competition from lower-cost, high-quality Indian drugs, which have gained significant popularity in the US due to their affordability and adherence to stringent manufacturing standards? Picture Credit: Freepik.com

• By Pooja Chaturvedi Sah
• New Delhi
• Jul 30, 2024

News

In the first quarter of the financial year 2024-25 (FY25), the approval rate of new drugs from major Indian pharmaceutical companies plummeted to its lowest level in eight quarters. According to the media reports, this drastic decline coincides with intensified regulatory scrutiny from the US Food and Drug Administration (USFDA), raising critical questions about the motivations behind such stringent oversight. 

Are these measures genuinely about quality control, or is the USFDA being leveraged as a tool to protect domestic pharmaceutical interests? 

Regulatory Approvals and Inspections: The Numbers Speak 

The data is telling. Major Indian pharmaceutical companies like Cipla, Sun Pharma, Aurobindo Pharma, Dr. Reddy’s, and Lupin have all faced increased scrutiny from the USFDA, resulting in numerous inspections and warning letters. 

Aurobindo Pharma, for instance, witnessed a sharp decline in new drug approvals due to regulatory issues at its unit III manufacturing facility. The company, which holds 507 ANDA approvals (488 final and 19 tentative), received seven observations for its unit-II formulation facility in Bhiwadi, Rajasthan, in May, adding to three observations for its new injectable facility in Andhra Pradesh earlier this year. 

Cipla’s Goa facility received six inspectional observations in Form 483 following a USFDA inspection in June. Despite these hurdles, Cipla reported a 7% increase in revenue to Rs 6,694 crore and an 18% rise in net profit to Rs 1,178 crore for Q1 FY25, driven by robust performances in both India and the US markets. 

Quality Concerns Over Indian Manufactured Drugs: Legitimate or Overblown? 

The Center for Drug Evaluation and Research (CDER), a division of the USFDA, reported violations in 11% of the Indian facilities it inspected, citing data integrity issues among other concerns. This has led to the pilot launch of the Quality Management Maturity (QMM) program by the USFDA, aiming to enhance the supply chain and reduce drug shortages through better quality management practices. 

However, critics argue that these measures disproportionately target Indian companies, which have a strong record of adhering to stringent manufacturing standards. The timing and frequency of inspections and notices have raised suspicions of protectionist motives, particularly given the competitive threat posed by affordable Indian generics to the highly lucrative US pharmaceutical market. 

The Financial Stakes: Growth Despite Hurdles 

Despite the regulatory challenges, Indian pharmaceutical companies continue to experience growth in the US market. The US business for these companies is expected to grow by 2-4% quarter-on-quarter and around 8% year-on-year, driven by stable pricing and new product launches. 

Notable launches include generic versions of blockbuster drugs like Revlimid (cancer treatment) and Spiriva (respiratory drug), which are anticipated to significantly boost revenues. Overall, these companies are projected to see a modest 9% year-on-year revenue growth, with the India business potentially growing faster at 10% due to seasonal demand for acute products. 

The robust financial performance of these companies, despite regulatory barriers, underscores their resilience and the sustained demand for their products in the US market. 

Form 483: A Tool for Regulation or Competition Suppression? 

In what appears to be an effort to curb competition from Indian pharmaceutical companies, the USFDA has served Form 483 notices to eight major Indian companies since the start of this year. These notices, highlighting objectionable conditions observed during inspections, were issued to Cipla, Torrent Pharmaceuticals, Dr. Reddy’s Laboratories, Laurus Synthesis, Eugia Pharma, Zydus Lifesciences, Alkem Laboratories, and Jubilant Generics. The Form 483 notices ostensibly aim to enforce high-quality standards in drug production. 

However, industry insiders argue that this regulatory tool is being wielded selectively to stifle competition from lower-cost, high-quality Indian drugs, which have gained significant popularity in the US due to their affordability and adherence to stringent manufacturing standards. 

The Impact of Indian Pharma on the US Market 

Despite these regulatory obstacles, Indian pharma exports to the US surged to $7.83 billion during the April-February period in 2024, up from $6.8 billion in the same period in FY23. India's total pharmaceutical exports increased by 9.34% to $25.04 billion, with the US contributing to about 30% of these exports. 

Indian-manufactured drugs are significantly cheaper than their American counterparts due to lower manufacturing and labor costs in India, without compromising on quality. Many Indian pharmaceutical companies operate facilities approved by the USFDA, ensuring their products meet the rigorous American standards. 

Bilateral Cooperation and Quality Assurance: The Hidden Agenda? 

The popularity of Indian-manufactured drugs among American consumers, driven by their affordability and quality, has led to increased bilateral cooperation between India and the US. In February 2020, the USFDA conducted Operation Broadsword, its first bilateral enforcement operation with the Indian government. This joint effort successfully intercepted around 500 shipments of illicit and potentially dangerous unapproved prescription drugs and combination medical devices destined for American consumers. 

Such collaborations underscore the importance of maintaining high-quality standards while ensuring that the regulatory framework is not misused to unfairly disadvantage foreign competitors. 

The USFDA’s Form 483 observations are intended as inspectional observations and do not represent a final agency determination regarding compliance. Companies are given the opportunity to address and correct these observations in coordination with the USFDA. 

The Broader Implications: Quality Control or Market Manipulation? 

The scrutiny faced by Indian pharmaceutical companies in the US raises important questions about the balance between genuine quality control and protectionist measures. While ensuring the safety and efficacy of drugs is paramount, it is equally crucial to prevent the misuse of regulatory frameworks as tools for market manipulation. The ongoing challenges highlight the need for a fair and transparent regulatory environment that supports innovation and competition. 

As healthcare costs continue to soar in the US, the demand for affordable, high-quality medications from countries like India will only increase. It is imperative that regulatory practices foster a competitive marketplace that benefits consumers through access to safe, effective, and affordable drugs. 

The Influence of Big Pharma on US Regulatory Practices 

Big Pharma's influence on US regulatory practices cannot be ignored. The pharmaceutical industry is one of the most powerful lobbying groups in the United States, wielding significant influence over policy decisions. This influence extends to the regulatory actions of the USFDA, where the lines between genuine quality control and protectionist practices often blur. The strategic use of Form 483 notices against Indian pharmaceutical companies highlights this influence. 

By leveraging regulatory scrutiny, Big Pharma can delay or block the entry of competitive generics into the US market, maintaining their market dominance and high profit margins. The high cost of drugs in the US, often several times higher than in other countries, underscores the need for affordable alternatives. 

Conclusion: A Call for Regulatory Fairness 

The drastic decline in the approval rate of new drugs from Indian pharmaceutical companies in the first quarter of FY25, amidst intensified USFDA scrutiny, underscores the pressing need for a balanced regulatory approach. While ensuring drug quality and safety is critical, it is equally important to avoid the misuse of regulatory measures as barriers to competition. 

The USFDA’s heightened oversight, marked by numerous Form 483 notices, has disproportionately targeted Indian pharmaceutical companies, raising concerns about protectionist motives. Despite these challenges, Indian pharma continues to grow in the US market, driven by the demand for affordable and high-quality medications. 

To foster a fair and competitive marketplace, regulatory practices must strike a balance between maintaining high standards and encouraging innovation and competition. As the global healthcare landscape evolves, ensuring access to safe, effective, and affordable drugs will be paramount. This requires a commitment to transparency and fairness in regulatory processes, free from undue influence by powerful industry players. The future of global healthcare depends on it.